I think everybody admits it
Do I need an operative report to file, or will ER imaging be enough
Etiology Autoimmune Autoantibodies directed against postsynaptic acetylcholine receptors or receptor-associated proteins Most common: acetylcholine receptor antibodies (AChR-Ab) Less common: muscle-specific tyrosine kinase antibodies (MuSK-Ab), lipoprotein receptor-related protein antibodies (LRP4-Ab), or no detectable antibodies Association with other autoimmune diseases, including: A minority of patients with myasthenia gravis have no detectable antibodies (i.e., seronegative MG)
D-carnitine is a competitive inhibitor of L-carnitine
On April 30, 2026, the FDA moved further - formally proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely, citing no clinical need for large-scale outsourcing facilities to compound these drugs from bulk substances